Third Harmonic Bio Closes Upsized Initial Public Offering of Shares of Common Stock Trading on the NASDAQ Global Market
CFGI’s Life Sciences team assisted Third Harmonic Bio (NASDAQ: THRD) with their initial public offering.
CFGI’s Life Sciences team assisted Third Harmonic Bio (NASDAQ: THRD) with their initial public offering.
Each year at the AICPA & CIMA Conference, prominent members of the SEC, PCAOB, FASB, IASB and others meet to recap the year in regulation and discuss key initiatives and current developments.
By John Kahn, Partner, CFGI You may have heard about the massive spike in popularity of SPACs, but have you heard about Zombie SPACs and Blood Baths? Writing this in Atlanta, Georgia, home of “The Walking Dead” TV show, makes it easier to appreciate that a “Zombie SPAC” is a SPAC without enough life left… More
CFGI’s Capital Markets team assisted Senti Biosciences, Incorporated (“Senti Bio”) with the completion of its merger with Dynamics Special Purpose Corporation (“DYNS”) (Nasdaq: DYNS), a special purpose acquisition company.
Background The SEC issued a long-anticipated proposed rule on March 21, 2022, surrounding the potential standardization of requirements for climate-related disclosures in registration statements and annual reports of public filers.
CFGI’s Capital Markets team assisted privately-owned BCP Raptor Holdco LP (“BCP”), the parent company of EagleClaw Midstream, with the completion of an all-stock business combination with Altus Midstream Company (Nasdaq: ALTM) (“Altus”), creating a unique, fully-integrated midstream company.
2021 was an exciting year of growth for CFGI, which included a new partnership with CVC Capital Partners, one of the world’s largest private equity firms.
CFGI’s Capital Markets team assisted Enjoy Technology, Inc.